APOB and metabolic syndrome: According to the 2019 ESC/EAS Guidelines for the management of dyslipidemia regarding lipid modification to reduce cardiovascular risk, ApoB measurements are recommended as a class I indication instead of LDL-C for primary screening, diagnosis, and management.